N4 Pharma Plc (AIM:N4P) Admission to AIM/Interview with CEO

Summary:

·     Change of name to N4 Pharma Plc (formerly Onzima Ventures Plc) effective

·     £1.5 million (gross) raised by way of a placing of 21,428,571 New Ordinary Shares at 7p per share

·     The number of Ordinary Shares in issue immediately after Admission will be 71,714,258 giving the Company a market capitalisation of £5 million at the placing price of 7p per ordinary share

·     The net proceeds of the placing will be used to fund development of additional patent applications for reformulations of a wide range of generic drugs, to undertake clinical trials for N4 Pharma’s reformulation of sildenafil, commonly known as Viagra, and for working capital purposes

Defined terms used in this announcement shall have the same meaning as in the Company’s admission document published on 13 April 2017, copies of which are available at www.n4pharma.com

N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to announce the readmission today of the Company’s ordinary shares to trading on AIM and the commencement of dealings in the New Ordinary Shares under the ticker N4P (“Admission”).

Share Talk took the opportunity to speak with N4 Pharma’s Founder and CEO Nigel Theobald following their admission and first day of shares being available for dealing on AIM .

Listen now to CEO Nigel Theobald on what N4 Pharma has to offer.

Summary:

· Change of name to N4 Pharma Plc (formerly Onzima Ventures Plc) effective

· £1.5 million (gross) raised by way of a placing of 21,428,571 New Ordinary Shares at 7p per share

· The number of Ordinary Shares in issue immediately after Admission will be 71,714,258 giving the Company a market capitalisation of £5 million at the placing price of 7p per ordinary share

· The net proceeds of the placing will be used to fund development of additional patent applications for reformulations of a wide range of generic drugs, to undertake clinical trials for N4 Pharma’s reformulation of sildenafil, commonly known as Viagra, and for working capital purposes

Defined terms used in this announcement shall have the same meaning as in the Company’s admission document published on 13 April 2017, copies of which are available at: www.n4pharma.com

Nigel Theobald, CEO of N4 Pharma, commented:

“I am delighted that the acquisition has been completed after what has been a difficult few months for Onzima’s shareholders. Today’s listing on AIM marks an important milestone in the continued growth of N4 Pharma and I am determined to reward the patience of existing shareholders and look forward to rewarding those new shareholders who have joined us as part of the Admission.

“Reformulating drugs that are either off patent or coming off patent enables us to improve the experience for their end users in a number of potential ways, but in so doing ensuring we have patent protection around these new versions of the products. Our immediate focus is on the reformulation of sildenafil, commonly known as Viagra, for the treatment of erectile dysfunction, a market which had global annual sales in 2016 of approximately $4.6 billion* and more will follow in the coming months.

“The Board has extensive experience in this field, both from a pharmaceutical and commercial point of view and, in Opal IP, we have the ideal partner for our patent work.

“Our vaccine delivery system continues to be encouraging and we will demonstrate its point of difference with a view to ‘launching’ it to the vaccine community later this year.”

*source: Evaluate Pharma

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.

Terms of Website Use

All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Power Metal Resources

Malcare WordPress Security